- Home
- NXT vs ROIV Comparison
NXT vs ROIV Comparison
Compare NXT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXT
- ROIV
- Stock Information
- Founded
- NXT 2013
- ROIV 2014
- Country
- NXT United States
- ROIV United Kingdom
- Employees
- NXT N/A
- ROIV N/A
- Industry
- NXT Semiconductors
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- NXT Technology
- ROIV Health Care
- Exchange
- NXT Nasdaq
- ROIV Nasdaq
- Market Cap
- NXT 7.2B
- ROIV 8.4B
- IPO Year
- NXT 2023
- ROIV N/A
- Fundamental
- Price
- NXT $45.16
- ROIV $10.42
- Analyst Decision
- NXT Strong Buy
- ROIV Strong Buy
- Analyst Count
- NXT 20
- ROIV 7
- Target Price
- NXT $56.00
- ROIV $18.08
- AVG Volume (30 Days)
- NXT 2.2M
- ROIV 4.7M
- Earning Date
- NXT 01-28-2025
- ROIV 02-10-2025
- Dividend Yield
- NXT N/A
- ROIV N/A
- EPS Growth
- NXT 111.73
- ROIV N/A
- EPS
- NXT 3.48
- ROIV N/A
- Revenue
- NXT $2,771,370,000.00
- ROIV $122,585,000.00
- Revenue This Year
- NXT $15.81
- ROIV N/A
- Revenue Next Year
- NXT $11.33
- ROIV N/A
- P/E Ratio
- NXT $12.95
- ROIV N/A
- Revenue Growth
- NXT 21.46
- ROIV 140.04
- 52 Week Low
- NXT $30.93
- ROIV $9.76
- 52 Week High
- NXT $62.31
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- NXT 52.61
- ROIV 43.62
- Support Level
- NXT $40.21
- ROIV $10.39
- Resistance Level
- NXT $45.66
- ROIV $10.81
- Average True Range (ATR)
- NXT 2.18
- ROIV 0.35
- MACD
- NXT -0.15
- ROIV 0.03
- Stochastic Oscillator
- NXT 60.15
- ROIV 52.87
About NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.